Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

(2020) G R Lichtenstein et al.   Journal of Crohns & Colitis

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

(2020) Philip Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

ACG Clinical Guideline

(2019) David T. Rubin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis

(2019) Rujia Xie et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

(2019) William J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial

(2018) Arnab Mukherjee et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

(2018) Kevin L Winthrop et al.   INFLAMMATORY BOWEL DISEASES

Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn’s Disease at a Tertiary Referral Center

(2018) Peter Hoffmann et al.   DIGESTIVE DISEASES

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

(2018) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines

(2016) Silvio Danese et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohnʼs Disease

(2015) Shringi Sharma et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease

(2013) Sriram Krishnaswami et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

(2011) A.A. Fasanmade et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

(2010) Asher Kornbluth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY